| Audrey Bergeson, MD | |
|
1034 N 500 W, Provo, UT 84604-3380 | |
| (801) 357-7850 | |
| Not Available |
| Full Name | Audrey Bergeson |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 1034 N 500 W, Provo, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427478577 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | Q9957 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | BP10049734 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | 11439161-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Valley Emergency Physicians Inc | 2860390879 | 34 |
News Archive
Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation.
› Verified 5 days ago
| Entity Name | Utah Valley Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649204553 PECOS PAC ID: 2860390879 Enrollment ID: O20040727000274 |
News Archive
Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation.
› Verified 5 days ago
| Entity Name | Castleview Physician Practice, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013364884 PECOS PAC ID: 6305995598 Enrollment ID: O20090518000607 |
News Archive
Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation.
› Verified 5 days ago
| Entity Name | West Emergency Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548929565 PECOS PAC ID: 1850785296 Enrollment ID: O20220228002097 |
News Archive
Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Audrey Bergeson, MD Po Box 10, Spanish Fork, UT 84660-0019 Ph: (330) 903-3294 | Audrey Bergeson, MD 1034 N 500 W, Provo, UT 84604-3380 Ph: (801) 357-7850 |
News Archive
Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation.
› Verified 5 days ago
Adam R Krommenhoek, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-373-7850 | |
Dr. Christopher Nathan Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7850 | |
Craig P Patten, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1034 North 500 West, Provo, UT 84604 Phone: 801-373-7850 | |
Robert D Christensen, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7850 | |
Andrew Pressman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7850 | |
Mr. Tanner Lee Frey, PHYSICIAN ASSISTANT Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-358-1076 | |
Dr. Cameron Royall, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-362-4119 |